Latest stories on XLO
Xilio Therapeutics GAAP EPS of -$0.33, revenue of $18.7M
Seeking Alpha56 · neutralearnings
Xilio Therapeutics, Inc. (XLO) files 8-K
SEC 8-K50 · neutralgeneral
Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates
Business Insider59 · neutralproduct/pr
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | XLO Stock News
StockTitan50 · neutralgeneral
Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer | XLO Stock News
StockTitan55 · neutralgeneral
Xilio Therapeutics Adjusts Board Structure Following Shareholder Votes
TipRanks50 · neutralgeneral
Xilio Therapeutics, Inc. (XLO) files 8-K
SEC 8-K50 · neutralgeneral